A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
Nizatidine (Axid) is the newest of four histamine receptor antagonists approved by the Food and Drug Administration for treatment of duodenal ulcer and maintenance therapy. It is as effective as the other histamine blockers in healing active duodenal ulcers and in the prevention of relapse. Nizatidine is comparable in price to cimetidine (Tagamet). Nizatidine does not interfere with the hepatic metabolism of other drugs. No significant central nervous system side effects have been reported. It is safe to use in elderly patients or in patients with renal insufficiency. The dosage, however, should be decreased when renal function is impaired.